Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APC | P25054 | 3/20 | 0.42 |
| ▸ | GRPR | P30550 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.40 |
| ▸ | CCKBR | P32239 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478119 | 0.82 | CCKBR (0.57) | CCKBR | |
| SCHEMBL14478149 | 0.81 | APC (0.54) | APCKEAP1PTPN1 | |
| SCHEMBL30659885 | 0.79 | APC (0.44) | APCGRPRKEAP1CCKBRF2 | |
| SCHEMBL20230288 | 0.78 | MMP8 (0.40) | APCGRPRCCKBRCTSSCTSK | |
| SCHEMBL6869254 | 0.77 | MMP12 (0.57) | — | |
| SCHEMBL14122466 | 0.77 | MMP12 (0.57) | — | |
| SCHEMBL14478086 | 0.77 | MME (0.43) | APCKEAP1FOLH1CTSSCTSK | |
| SCHEMBL14478103 | 0.76 | APC (0.60) | APCCCKBR | |
| SCHEMBL29582481 | 0.76 | NAALAD2 (0.46) | APCCCKBRF2 | |
| SCHEMBL14122822 | 0.75 | MMP12 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106460-A1 | BINDING INHIBITORS OF THE BETA. TRANSDUCIN REPEAT-CONTAINING PROTEIN | BRADLEY MARK (GB) | 2019-04-11 | — | — | US | disclosed |
| WO-2013001297-A1 | BINDING INHIBITORS OF THE BETA.TRANSDUCIN REPEAT - CONTAINING PROTEIN | ITI SCOTLAND LIMITED (GB) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106460-A1 | BINDING INHIBITORS OF THE BETA. TRANSDUCIN REPEAT-CONTAINING PROTEIN | TARDBP, DDB1, EPS15 | APC 1546/4885GRPR 3115/4885KEAP1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.